EUVIMEDEUVIMED entdecken
Open Access

Efficacy of Lacosamide and Rufinamide as Adjuncts to Midazolam-Ketamine Treatment Against Cholinergic-Induced Status Epilepticus in Rats

Lucille A Lumley iD, Donna A Nguyen, Marcio de Araujo Furtado, Jerome Niquet iD, Emily O Linz, Caroline R Schultz iD, Michael F Stone, Claude G Wasterlain iD

The Journal of Pharmacology and Experimental Therapeutics · 2024

DOI: 10.1124/jpet.123.001789 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024. Verfasst von Lucille A Lumley und 7 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Department, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland (L.A.L., D.A.N., E.O.L., C.R.S.,…. Hauptthemen laut MEDLINE: Ketamine, Soman, Status Epilepticus, Triazoles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Benzodiazepine pharmacoresistance develops when treatment of status epilepticus (SE) is delayed. This response may result from gamma-aminobutyric acid A receptors (GABAAR) internalization that follows prolonged SE; this receptor trafficking results in fewer GABAAR in the synapse to restore inhibition. Increase in synaptic N-methyl-D-aspartate receptors (NMDAR) also occurs in rodent models of SE. Lacosamide, a third-generation antiseizure medication (ASM), acts on the slow inactivation of voltage-gated sodium channels. Another ASM, rufinamide, similarly acts on sodium channels by extending the duration of time spent in the inactivation stage. Combination therapy of the benzodiazepine midazolam, NMDAR antagonist ketamine, and ASMs lacosamide (or rufinamide) was investigated for efficacy against soman (GD)-induced SE and neuropathology. Adult male rats implanted with telemetry transmitters for monitoring electroencephalographic (EEG) activity were exposed to a seizure-inducing dose of GD and treated with an admix of atropine sulfate and HI-6 1 minute later and with midazolam monotherapy or combination therapy 40 minutes after EEG seizure onset. Rats were monitored continuously for seizure activity for two weeks, after which brains were processed for assessment of neurodegeneration, neuronal loss, and neuroinflammatory responses. Simultaneous administration of midazolam, ketamine, and lacosamide (or rufinamide) was more protective against GD-induced SE compared with midazolam monotherapy. In general, lacosamide triple therapy had more positive outcomes on measures of epileptogenesis, EEG power integral, and the number of brain regions protected from neuropathology compared with rats treated with rufinamide triple therapy. Overall, both drugs were well tolerated in these combination models. SIGNIFICANCE STATEMENT: We currently report on improved efficacy of antiseizure medications lacosamide and rufinamide, each administered in combination with ketamine (NMDAR antagonist) and midazolam (benzodiazepine), in combatting soman (GD)-induced seizure, epileptogenesis, and brain pathology over that provided by midazolam monotherapy, or dual therapy of midazolam and lacosamide (or rufinamide) in rats. Administration of lacosamide as adjunct to midazolam and ketamine was particularly effective against GD-induced toxicity. However, protection was incomplete, suggesting the need for further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineSomanStatus EpilepticusTriazolesRatsMaleAnimalsMidazolamLacosamideAnticonvulsantsSeizuresBenzodiazepinesCholinergic Agentsgamma-Aminobutyric Acid

Substanzen

MidazolamLacosamideKetaminerufinamideSomanAnticonvulsantsBenzodiazepinesCholinergic Agentsgamma-Aminobutyric AcidTriazoles

Autor:innen und Institutionen

  • Neuroscience Department, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland (L.A.L., D.A.N., E.O.L., C.R.S., M.F.S.); BioSEaD, LLC, Rockville, Maryland (M.d.A.F.); and Department…

ORCID-Profile: Lucille A Lumley, Jerome Niquet, Caroline R Schultz, Claude G Wasterlain

Förderung

  • NINDS NIH HHS
  • NIH HHS

Zitieren

APA

Lumley, L. A., Nguyen, D. A., de Araujo Furtado, M., Niquet, J., Linz, E. O., Schultz, C. R., Stone, M. F., & Wasterlain, C. G. (2024). Efficacy of Lacosamide and Rufinamide as Adjuncts to Midazolam-Ketamine Treatment Against Cholinergic-Induced Status Epilepticus in Rats. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.123.001789

Vancouver

Lumley LA, Nguyen DA, de Araujo Furtado M, Niquet J, Linz EO, Schultz CR, et al. Efficacy of Lacosamide and Rufinamide as Adjuncts to Midazolam-Ketamine Treatment Against Cholinergic-Induced Status Epilepticus in Rats. The Journal of Pharmacology and Experimental Therapeutics. 2024. doi:10.1124/jpet.123.001789

BibTeX
@article{Lumley2024,
  author = {Lumley, Lucille A and Nguyen, Donna A and de Araujo Furtado, Marcio and Niquet, Jerome and Linz, Emily O and Schultz, Caroline R and Stone, Michael F and Wasterlain, Claude G},
  title = {Efficacy of Lacosamide and Rufinamide as Adjuncts to Midazolam-Ketamine Treatment Against Cholinergic-Induced Status Epilepticus in Rats},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2024},
  doi = {10.1124/jpet.123.001789}
}
Kostenlos starten →